Fig. 3
MB-exos inhibit RSL3- or erastin-induced ferroptosis of endometrial stromal cells. A ESC cell proliferation was examined by EdU staining after erastin (10 μM) treatment with/without B-exos or MB-exos (n = 3/group). B–E Iron accumulation, GSSG levels, MDA production, and GSH depletion were measured in each group (control, erastin, B-exos + erastin, and MB-exos + erastin) (n = 3/group) [n.s.: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001]. ESCs were subjected to RSL3 (2.5 μM) treatment with/without B-exos or MB-exos. (F) Cell proliferation was evaluated by EdU staining (n = 3/group). G–J Iron accumulation, GSSG levels, GSH depletion, and MDA production were measured in each group (control, RSL3, B-exos + RSL3, and MB-exos + RSL3) [*P < 0.05, **P < 0.01, ***P < 0.001] (n = 3/group)